Alfred DSouza - Biosyent Advisor
RX Stock | CAD 11.25 0.02 0.18% |
Executive
Mr. Alfred DSouza serves as Chief Financial Officer of Biosyent Inc. Mr. DSouza is a Certified Management Accountant and Masters of Business Administration who joined BioSyent as Controller and Director of Finance in October 2006. Prior to joining BioSyent, Mr. DSouza enjoyed a 16 year career with progressive management assignments at ColgatePalmolive Company. Mr. DSouza last two positions at ColgatePalmolive were Head of Finance at ColgatePalmolive Vietnam and most recently as Finance Director and Controller of ColgatePalmolive India. since 2013.
Tenure | 12 years |
Phone | 905 206 0013 |
Web | https://www.biosyent.com |
Biosyent Management Efficiency
The company has return on total asset (ROA) of 0.1191 % which means that it generated a profit of $0.1191 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1977 %, meaning that it created $0.1977 on every $100 dollars invested by stockholders. Biosyent's management efficiency ratios could be used to measure how well Biosyent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Katie Martinovich | Covalon Technologies | N/A | |
Kimberley Crooks | Covalon Technologies | N/A | |
Monica Percario | Knight Therapeutics | N/A | |
Mark Doolittle | Covalon Technologies | N/A | |
Stephani Saverio | Knight Therapeutics | N/A | |
Hamed Abbasian | Covalon Technologies | N/A | |
Hamed Ghanei | Cipher Pharmaceuticals | N/A | |
Melanie Groleau | Knight Therapeutics | N/A | |
Shengnan Guo | Cipher Pharmaceuticals | N/A | |
Henrique Dias | Knight Therapeutics | N/A | |
Elaine Zhang | Covalon Technologies | N/A | |
Diane Gajewczyk | Cipher Pharmaceuticals | N/A | |
Susan Emblem | Knight Therapeutics | N/A | |
Ronald Hebert | Covalon Technologies | N/A | |
Greg Leszczynski | Covalon Technologies | N/A | |
Ryan Mailling | Cipher Pharmaceuticals | N/A |
Management Performance
Biosyent Leadership Team
Elected by the shareholders, the Biosyent's board of directors comprises two types of representatives: Biosyent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosyent. The board's role is to monitor Biosyent's management team and ensure that shareholders' interests are well served. Biosyent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosyent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alfred DSouza, Advisor | ||
Neelu Atwal, Director Resources | ||
Ren Goehrum, CEO Chairman | ||
Robert March, CFO, Senior Vice President - Finance | ||
Joost Mark, Vice Development | ||
Kevin Wilson, Vice Sales |
Biosyent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biosyent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biosyent Stock Analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.